General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (the PACE study): Study protocol for a randomised controlled trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Bates, Janine ^a   Francis, Nick A ^b   White, Patrick ^c   Gillespie, David ^a   Thomas Jones, Emma ^a   Breen, Rachel ^a   Kirby, Nigel ^a   Hood, Kerry ^a   Gal, Micaela ^b   Phillips, Rhiannon ^b   Naik, Gurudutt ^b   Cals, Jochen ^d   Llor, Carl ^e   Melbye, Hasse ^f   Wootton, Mandy ^g   Riga, Evgenia ^h   Cochrane, Ann ^c   Howe, Robin ^g   Fitzsimmons, Deborah ⁱ   Sewell, Bernadette ⁱ   Alam, Mohammed Fasihul ^j   Butler, Christopher C ^h   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Barcelona City Research Support Unit University Institute for Research in Primary Care Jordi Gol   (Spain)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ SWANSEA UNIVERSITY   (United Kingdom)

^j Qatar University   (Qatar)

more..

Author keywords

Acute exacerbation; Antibiotic resistance; C reactive protein (CRP); Chronic obstructive pulmonary disease; Cost effectiveness; Near patient testing; Point of care test; Primary care; Rationalising antibiotic prescribing; Resistance

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ACUTE DISEASE; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL STUDY; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG USE; ECONOMIC EVALUATION; FOLLOW UP; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PNEUMONIA; POINT OF CARE TESTING; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPUTUM; THROAT CULTURE; ATTITUDE TO HEALTH; BLOOD; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; INTENTION TO TREAT ANALYSIS; METHODOLOGY; MICROBIOLOGY; PREDICTIVE VALUE; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CLINICAL DECISION-MAKING; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG PRESCRIPTIONS; GENERAL PRACTICE; GENERAL PRACTITIONERS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS; HUMANS; INTENTION TO TREAT ANALYSIS; POINT-OF-CARE TESTING; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85030697887     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-2144-8     Document Type: Article

References (47)

1. O'Neill J. Rapid diagnostics: stopping unnecessary use of antibiotics. 2015. Available from: https://amr-review.org/sites/default/files/Paper-Rapid-Diagnostics-Stopping-Unnecessary-Prescription-Low-Res.pdf. Accessed 07 Sept 2017.
2. Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta. 2014;427:49-57.
3. Food and Drug Administration. Medical devices: overview of IVD regulation. Available from: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm123682.htm. Accessed 07 Sept 2017.
4. Ferrante Di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PMM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ (Online). 2012;344(7847), e686.
5. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ (Online). 2010;340(7756):1120.
6. Prescribing and Primary Care team HaSCIC. Quality and outcomes framework, achievements, prevalence and exception data: 2011-12. England: NHS-The Information Centre for Health and Social Care; 2012.
7. Llor C, Bjerrum L, Munck A, Hansen MP, Cordoba GC, Strandberg EL, et al. Predictors for antibiotic prescribing in patients with exacerbations of COPD in general practice. Ther Adv Respir Dis. 2013;7(3):131-7.
8. Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med. 1999;93(3):173-9.
9. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224-1238.
10. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58(1):37-42.
11. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of. Am J Respir Crit Care Med. 2010;181(2):150-7.
12. Anthonisen NRMJ, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
13. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD).2017. Available from: http://goldcopd.org. Accessed 07 Sept 2017.
14. Miravitlles M, Moragas A, Hernandez S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013;144(5):1571-1577.
15. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12, CD010257.
16. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-87.
17. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J Suppl. 2002;20(36):9s-19s.
18. Desai H, Richter S, Doern G, Heilmann K, Dohrn C, Johnson A, et al. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure. COPD. 2010;7(5):337-44.
19. Perez-Trallero E, Marimon JM, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis. 2005;41(4):560-4.
20. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999;14(5):1015-22.
21. Cosby JL, Francis N, Butler CC. The role of evidence in the decline of antibiotic use for common respiratory infections in primary care. Lancet Infect Dis. 2007;7(11):749-56.
22. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary. Am J Respir Crit Care Med. 2006;174(8):867-74.
23. Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716-23.
24. Garcha DS, Thurston SJ, Patel ARC, Mackay AJ, Goldring JJP, Donaldson GC, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075-80.
25. Ding X, Wu X, Yu C, Hu S. Value of C-reactive protein measurement in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease. [Chinese]. Med J Wuhan University. 2006;27(5):660-3.
26. Weis N, Almdal T. C-reactive protein-can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 2006;17(2):88-91.
27. Daniels JMA, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138(5):1108-15.
28. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410-8.
29. Al-ani S, Spigt M, Laue J, Melbye H. Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care. BMC Fam Pract. 2015;16(1):40.
30. Oppong R, Coast J, Hood K, Nuttall J, Smith RD, Butler CC. Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges. Eur J Health Econ. 2011;12(4):319-29.
31. Cals JWL, Ament AJHA, Hood K, Butler CC, Hopstaken RM, Wassink GF, et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract. 2011;17(6):1059-69.
32. Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S, Anthierens S, et al. Effects of Internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet. 2013;382(9900):1175-82.
33. Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Molstad S, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract. 2013;63(612):e465-e71.
34. Geary M, Pluddemann A, Thompson M, Wolstenholme J, Heneghan C, Price C. Diagnostic Technology: Point-of-care test (POCT) for C-reactive protein (CRP). Horizon Scan Report 0017. Primary Care Diagnostic Horizon Scanning. Oxford: University of Oxford; 2011. https://www.oxford.dec.nihr.ac.uk/files/reportsandresources/horizon-scanning-reports. Accessed 07 Sept 2017.
35. van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13.
36. Kocks JW, Tuinenga MG, Uil SM, et al. Health status measurement in COPD: the minimal clinically important difference of the Clinical COPD Questionnaire. Respir. 2006;7:62.
37. Oakley A, Strange V, Bonell C, Allen E, Stephenson J. Process evaluation in randomised controlled trials of complex interventions. BMJ. 2006;332(7538):413-6.
38. Cals JWL, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: Cluster randomised trial. BMJ (Online). 2009;338(7703):1112-5.
39. Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med. 2010;8(2):124-33.
40. Kocks JW, Tuinenga MG, Uil SM, Van den Berg JWK, Ståhl E, Van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006;7(1):1.
41. Offen W, Chuang-Sfein C, Dmitrienko A, Littman G, Maca J, Meyerson L, et al. Multiple co-primary endpoints: medical and statistical solutions-A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America. Drug Inf J. 2007;41(1):31-46.
42. Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM, et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain. 2008;139(3):485-93.
43. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. J Am Med Assoc. 2009;302(23):2557-64.
44. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;91(434):444-55.
45. Ritchie J, Spencer L. In: Bryman A, Burgess R, editors. Analyzing qualitative data. London: Routledge, 1994.
46. Halpin DMG, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3(7):619-23.
47. Huddy JR, Ni MZ, Barlow J, Majeed A, Hanna GB. Point-of-care C reactive protein for the diagnosis of lower respiratory tract infection in NHS primary care: a qualitative study of barriers and facilitators to adoption. BMJ Open. 2016;6(3), e009959.